Low-grade glioma (LGG) represent typically slowly growing primary brain tumors with world health organization (WHO) grade I or II who affect young adults around their fourth decade. Radiological feature on MRI is a predominantly T2 hyperintense signal, LGG show typically no contrast uptake. Radiotherapy plays an important role in the treatment of LGG. However, not least because of the good prognosis with long term survivorship the timing of radiotherapy has been discussed controversially. In order to avoid long term sequelae such as neurocognitive impairment, malignant transformation or secondary neoplasms initiation was often postponed as long as possible
Age > 18 years
histologically proven low-grade glioma
indication for definitive or adjuvant radiotherapy
ability to understand character and personal consequences of the clinical trial
previous cerebral irradiation
contraindication for contrast-enhanced MRI
neurofibromatosis
participation in another clinical trial with competing objectives
Parallel
model-guided optimization of treatment plan
Other interventionoriginal treatmant plans are optimized based on model-based NTCP
standard treatment plan, no optimization
Other interventionoriginal treatment plans are not optimized
incidence of contrast enhancing brain leasions
the cumulative incidence of contrast enhancing brain lesions
radiation-induced brain injuries
incidence of radiation-induced brain injuries \> CTC°II
progression-free survival
number of surviving patients without tumor progression
overall survival
number of surviving patients
patient reported outcome
patient reported outcome according to points on the PRO-CTCAE questionaire, scored 0/1 for absent/present)
Click on the lead sponsor to view all of their trials.
